UT Health San Antonio’s $1 billion multiyear investment helps meet demand for care

July 17, 2026

Healthcare is a strong economic driver in San Antonio, generating more than $43 billion annually and supporting nearly 200,000 jobs across the region, according to the San Antonio Chamber of Commerce. As the region’s academic health center, UT Health San Antonio contributes approximately $3.2 billion annually through patient care, research, education and workforce development.




AI-assisted colonoscopy enhances polyp detection

May 20, 2026

UT Health San Antonio is using AI-assisted colonoscopy technology to help physicians detect precancerous polyps in real time, expanding access to advanced colorectal cancer prevention and early detection for South Texans.

A doctor holds a human colon anatomy model, demonstrating the digestive system's structure to diagnose and treat various gastrointestinal diseases and conditions.


Wellness 360 Pediatrics earns Level 1 Trauma-Informed Care Certification

April 9, 2026

UT Health San Antonio’s Wellness 360 Pediatrics nursing practice has earned Level 1 Trauma-Informed Care certification from the Ecumenical Center, joining a growing coalition of Bexar County organizations committed to delivering care that heals without causing further harm.

Happy child, girl and stethoscope of health provider for medical consulting, healthy lungs and listening to heartbeat. Face of laughing kid, pediatrician and chest assessment for healthcare analysis in clinic.



Bringing advanced neurological care to South Texas families

March 6, 2026

For patients and families navigating that uncertainty, UT Health San Antonio, the academic health center of The University of Texas at San Antonio, continues to build one of the region’s most comprehensive neurological care ecosystems through a network of expert clinicians, multidisciplinary teams, advanced diagnostics and nationally recognized researchers.




Widely used metabolic drugs may help curb rising colorectal cancer in younger adults

March 2, 2026

A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists — medications that are widely prescribed for metabolic disease — have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.